Login to Your Account



Other News To Note


Wednesday, November 28, 2012
• Atox Bio Ltd., of Ness Ziona, Israel, reported top-line results from a Phase IIa trial showing that AB103, a short peptide immune regulatory therapy, produced meaningful improvement across multiple endpoints vs. placebo in patients with necrotizing soft-tissue infections.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription